BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 29317067)

  • 1. Nigral depigmentation reflects monoamine exhaustion as initial step to Parkinson's disease.
    Müller T; Kohlhepp W
    Med Hypotheses; 2018 Jan; 110():46-49. PubMed ID: 29317067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease.
    Sulzer D
    Trends Neurosci; 2007 May; 30(5):244-50. PubMed ID: 17418429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
    Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
    Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The vulnerability of nigral neurons to Parkinson's disease is unrelated to their intrinsic capacity for dopamine synthesis: an in situ hybridization study.
    Kingsbury AE; Marsden CD; Foster OJ
    Mov Disord; 1999 Mar; 14(2):206-18. PubMed ID: 10091611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders.
    Tong J; Rathitharan G; Meyer JH; Furukawa Y; Ang LC; Boileau I; Guttman M; Hornykiewicz O; Kish SJ
    Brain; 2017 Sep; 140(9):2460-2474. PubMed ID: 29050386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trichloroethylene and Parkinson's Disease: Risk Assessment.
    Liu M; Shin EJ; Dang DK; Jin CH; Lee PH; Jeong JH; Park SJ; Kim YS; Xing B; Xin T; Bing G; Kim HC
    Mol Neurobiol; 2018 Jul; 55(7):6201-6214. PubMed ID: 29270919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease.
    Zhang W; Wang T; Pei Z; Miller DS; Wu X; Block ML; Wilson B; Zhang W; Zhou Y; Hong JS; Zhang J
    FASEB J; 2005 Apr; 19(6):533-42. PubMed ID: 15791003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
    Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
    Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteomic approach to studying Parkinson's disease.
    Zhang J; Goodlett DR
    Mol Neurobiol; 2004 Jun; 29(3):271-88. PubMed ID: 15181239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression.
    Maingay M; Romero-Ramos M; Carta M; Kirik D
    Neurobiol Dis; 2006 Sep; 23(3):522-32. PubMed ID: 16806952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease?
    Chu Y; Kordower JH
    Neurobiol Dis; 2007 Jan; 25(1):134-49. PubMed ID: 17055279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship among alpha-synuclein accumulation, dopamine synthesis, and neurodegeneration in Parkinson disease substantia nigra.
    Mori F; Nishie M; Kakita A; Yoshimoto M; Takahashi H; Wakabayashi K
    J Neuropathol Exp Neurol; 2006 Aug; 65(8):808-15. PubMed ID: 16896314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain tyrosinase overexpression implicates age-dependent neuromelanin production in Parkinson's disease pathogenesis.
    Carballo-Carbajal I; Laguna A; Romero-Giménez J; Cuadros T; Bové J; Martinez-Vicente M; Parent A; Gonzalez-Sepulveda M; Peñuelas N; Torra A; Rodríguez-Galván B; Ballabio A; Hasegawa T; Bortolozzi A; Gelpi E; Vila M
    Nat Commun; 2019 Mar; 10(1):973. PubMed ID: 30846695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuronal vulnerability in Parkinson's disease.
    Double KL
    Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S52-4. PubMed ID: 22166454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys.
    Recasens A; Dehay B; Bové J; Carballo-Carbajal I; Dovero S; Pérez-Villalba A; Fernagut PO; Blesa J; Parent A; Perier C; Fariñas I; Obeso JA; Bezard E; Vila M
    Ann Neurol; 2014 Mar; 75(3):351-62. PubMed ID: 24243558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions.
    Chu Y; Dodiya H; Aebischer P; Olanow CW; Kordower JH
    Neurobiol Dis; 2009 Sep; 35(3):385-98. PubMed ID: 19505575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathogenesis of nigral cell death in Parkinson's disease.
    Przedborski S
    Parkinsonism Relat Disord; 2005 Jun; 11 Suppl 1():S3-7. PubMed ID: 15885625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
    Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
    Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dysregulated dopamine storage increases the vulnerability to α-synuclein in nigral neurons.
    Ulusoy A; Björklund T; Buck K; Kirik D
    Neurobiol Dis; 2012 Sep; 47(3):367-77. PubMed ID: 22659302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.